LFM-A13 | 2414

FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK). It has also been shown to inhibit Polo-like kinase (PLK) (IC₅₀ = 61 µM for human PLK3). It displays no activity (concentrations up to 278 µM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten tyrosine kinases.

FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK).

2414 | LFM-A13 DataSheet

Alternate Name/Synonyms: (2Z) -2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide

Appearance: White solid

Formulation: N/A

CAS Number: 244240-24-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₁H₈Br2N₂O₂

Molecular Weight: 360

Cell-Permeable?: Yes

Purity: ≥98% by TLC

Solubilities: DMSO (~15 mg/ml) or EtOH (~15 mg/ml)

Handling: Protect from light and air

Country of Origin: USA

Tag Line: A BTK inhibitor

MDL Number: MFCD09878279

PubChem CID: 54676905

SMILES: CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O

InChi: InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-

InChi Key: SVTDVJQAJIFG-VURMDHGXSA-N